Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

107

Enrollment

INDUSTRY

Sponsor class

Stopped Administrative reasons.

Conditions

Osteoarthritis

Interventions

DRUG: Buprenorphine transdermal patch
DRUG: Placebo transdermal patch

Sponsor

Purdue Pharma LP